ArticleBMC gastroenterology2025
Associations of urinary iodine concentration (UIC) with Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) among non-diabetic population: analysis of the NHANES 2017-2020.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease(MASLD) and diabetes are manifestations of metabolic syndrome. Urinary iodine concentration (UIC) is closely related to diabetes and glucose metabolism, but studies on the relationship between UIC and MASLD in non-diabetic individuals are limited. Our purpose was to explore the associations between UIC and MASLD as well as liver fibrosis in the non-diabetic population.
methodsWe analyzed data from the National Health and Nutrition Examination Survey (NHANES) conducted from 2017 to 2020. Participants were categorized into three groups based on UIC (µg/L): low (< 100), normal(100–299), and high(≥ 300). Vibration-controlled transient elastography (VCTE) was employed to measure the controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), which serve as indicators of MASLD and liver fibrosis, respectively. Multiple logistic regression was performed to evaluate the association between UIC and MASLD as well as liver fibrosis.
resultsThe study included 1281 non-diabetic participants aged ≥ 20 years. We found that high UIC was associated with a lower MASLD risk (OR = 0.57, 95%CI: 0.37–0.86, P = 0.008) compared to normal UIC. Stratified and sensitivity analyses confirmed these findings. The relationship between log2-UIC and MASLD was non-linear (P = 0.023), with a cutoff value of 84.62 µg/L. MASLD risk decreased rapidly when UIC exceeded this value. No significant association between UIC and liver fibrosis was observed.
conclusionsIn non-diabetic individuals, high UIC is associated with a lower MASLD prevalence, suggesting potential dietary interventions for MASLD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.